The United Kingdom has finalised a major pharmaceutical trade deal with the United States. This agreement allows medicines made in Britain to enter the U.S. market without any tariffs.
This tariff-free access will last for at least three years. It is part of a wider trade agreement signed earlier between the two countries. The deal is seen as an important step in strengthening economic ties, especially in the pharmaceutical sector.
The announcement was supported by Peter Kyle, who said the agreement would support the UK’s pharmaceutical industry and protect high-skilled jobs. The broader trade agreement was signed under leadership including Keir Starmer.
Pharmaceuticals are a key export for the UK. They account for about one-fifth of all goods exported from Britain to the United States by value. This highlights the importance of the U.S. market for British drugmakers.
The deal also protects British medicines, drug ingredients, and medical technology products from certain future U.S. tariffs. These protections are expected to remain until January 2029.
In addition, the agreement includes closer cooperation between regulators such as the Medicines and Healthcare products Regulatory Agency and the U.S. Food and Drug Administration. This aims to align rules and help new medical technologies reach patients faster.
U.S. prepares new tariffs targeting drug companies over pricing policies
UK Agrees to Higher Spending and Drug Prices
In exchange for tariff-free access, the United Kingdom has agreed to increase spending on medicines and change how drug prices are set.
Spending on medicines will rise from 0.3% of GDP to 0.35% by 2028. It is expected to increase further to 0.6% by 2035. This reflects a commitment to invest more in healthcare and new treatments.
The National Health Service (NHS) will also pay more for new medicines. From April 2026, the price paid for newly launched drugs will rise by 25%. This increase will apply only to medicines introduced after the agreement begins.
Changes will also be made to how new drugs are evaluated. The National Institute for Health and Care Excellence will adjust its framework to allow higher cost-effectiveness thresholds. This means more expensive medicines may be approved for use.
These steps are designed to make the UK more attractive for pharmaceutical companies. At the same time, they reflect U.S. concerns about global drug pricing. The approach has been shaped under the administration of Donald Trump.
Brazil reduces tariffs on 191 capital and technology goods amid supply concerns
Conditions, Industry Impact, and Policy Measures
The agreement includes strict conditions for companies. Tariff-free access depends on major UK pharmaceutical firms entering into and following separate pricing agreements with the U.S. government.
According to Jamieson Greer, there is a focus on ensuring that trading partners contribute fairly to the cost of developing new medicines. The U.S. has also warned that it may impose tariffs of up to 100% on branded drugs if companies do not meet pricing requirements or shift production domestically.
The deal also protects medical technology exports from additional tariffs. This is important for companies producing medical devices and equipment.
Another part of the agreement relates to the proposed “most favoured nation” pricing policy in the U.S. This policy aims to align American drug prices with those in other developed countries. The UK has been given assurances of certain protections if this policy is implemented.
Major pharmaceutical companies such as AstraZeneca and GSK have also signed separate agreements with the U.S. government. These agreements include protection from potential tariffs for three years.
The pharmaceutical terms were negotiated separately from the broader trade deal. Initial terms were outlined earlier, and the final agreement has now been confirmed. The deal reflects the growing link between trade policy, drug pricing, and healthcare spending.